Lobe Sciences Ltd. Engages ArcStone Securities for Strategic Capital Markets Advisory
Lobe Sciences (OTCQB:LOBEF), a biopharmaceutical company developing therapeutics for rare and underserved diseases, has engaged ArcStone Securities and Investments Corp. for capital markets advisory services. The partnership aims to enhance Lobe's market visibility and institutional investor engagement across North American markets.
Under the agreement, ArcStone will provide comprehensive advisory services including capital markets planning and strategic positioning. The collaboration is effective immediately, with ArcStone's expertise expected to support Lobe's development programs and strengthen its presence in both Canadian and U.S. financial markets.
Lobe Sciences (OTCQB:LOBEF), una societ脿 biofarmaceutica che sviluppa terapie per malattie rare e poco trattate, ha incaricato ArcStone Securities and Investments Corp. per servizi di consulenza sui mercati dei capitali. La collaborazione mira a migliorare la visibilit脿 di Lobe sul mercato e il coinvolgimento degli investitori istituzionali nei mercati nordamericani.
Secondo l'accordo, ArcStone fornir脿 servizi di consulenza completi, inclusa la pianificazione dei mercati dei capitali e il posizionamento strategico. La partnership 猫 gi脿 operativa e l'esperienza di ArcStone 猫 destinata a supportare i programmi di sviluppo di Lobe e a rafforzare la sua presenza nei mercati finanziari canadese e statunitense.
Lobe Sciences (OTCQB:LOBEF), una compa帽铆a biofarmac茅utica que desarrolla terapias para enfermedades raras y desatendidas, ha contratado a ArcStone Securities and Investments Corp. para servicios de asesor铆a en mercados de capitales. La alianza busca aumentar la visibilidad de Lobe en el mercado y la participaci贸n de inversores institucionales en los mercados norteamericanos.
Bajo el acuerdo, ArcStone brindar谩 servicios integrales de asesor铆a que incluyen planificaci贸n de mercados de capital y posicionamiento estrat茅gico. La colaboraci贸n es efectiva de inmediato y se espera que la experiencia de ArcStone apoye los programas de desarrollo de Lobe y fortalezca su presencia en los mercados financieros de Canad谩 y EE. UU.
Lobe Sciences (OTCQB:LOBEF)電� 頋穩 氚� 靻岇櫢 歆堩櫂 旃橂鞝滊ゼ 臧滊皽頃橂姅 氚旍澊鞓れ牅鞎� 須岇偓搿滌劀, ArcStone Securities and Investments Corp.鞕� 鞛愲掣 鞁滌灔 鞛愲 靹滊箘鞀� 瓿勳暯鞚� 觳搓舶頄堨姷雼堧嫟. 鞚措矆 順戨牓鞚� 攵侂 鞁滌灔 鞝勲皹鞐愳劀 Lobe鞚� 鞁滌灔 鞚胳霃勳檧 旮瓣磤 韴瀽鞛� 彀胳棳毳� 臧曧檾頃橂姅 瓴冹潉 氇╉憸搿� 頃╇媹雼�.
瓿勳暯鞐� 霐半澕 ArcStone電� 鞛愲掣 鞁滌灔 瓿勴殟 氚� 鞝勲灥鞝� 韽靺旊嫕鞚� 韽暔頃� 膦呿暕 鞛愲 靹滊箘鞀るゼ 鞝滉车頃� 鞓堨爼鞛呺媹雼�. 鞚� 順戨牓鞚� 歃夓嫓 氚滍毃霅橂┌, ArcStone鞚� 鞝勲靹膘潃 Lobe鞚� 臧滊皽 頂勲攴鸽灗 歆�鞗愱臣 旌愲倶雼� 氚� 氙戈淡 旮堨湹 鞁滌灔 雮� 鞛呾 臧曧檾鞐� 旮办棳頃� 瓴冹溂搿� 旮半寑霅╇媹雼�.
Lobe Sciences (OTCQB:LOBEF), une soci茅t茅 biopharmaceutique d茅veloppant des traitements pour des maladies rares et peu prises en charge, a fait appel 脿 ArcStone Securities and Investments Corp. pour des services de conseil sur les march茅s des capitaux. Ce partenariat vise 脿 accro卯tre la visibilit茅 de Lobe sur le march茅 et l'engagement des investisseurs institutionnels sur les march茅s nord-am茅ricains.
Dans le cadre de cet accord, ArcStone fournira des services de conseil complets, incluant la planification des march茅s des capitaux et le positionnement strat茅gique. La collaboration est effective imm茅diatement, l'expertise d'ArcStone devant soutenir les programmes de d茅veloppement de Lobe et renforcer sa pr茅sence sur les march茅s financiers canadien et am茅ricain.
Lobe Sciences (OTCQB:LOBEF), ein biopharmazeutisches Unternehmen, das Therapeutika f眉r seltene und unterversorgte Krankheiten entwickelt, hat ArcStone Securities and Investments Corp. mit Beratungsdienstleistungen f眉r Kapitalm盲rkte beauftragt. Die Partnerschaft zielt darauf ab, Lobes Marktpr盲senz und die Einbindung institutioneller Investoren in den nordamerikanischen M盲rkten zu verbessern.
Im Rahmen der Vereinbarung wird ArcStone umfassende Beratungsleistungen, einschlie脽lich Kapitalmarktplanung und strategischer Positionierung, erbringen. Die Zusammenarbeit ist sofort wirksam, wobei ArcStones Expertise erwartet wird, Lobes Entwicklungsprogramme zu unterst眉tzen und die Pr盲senz in den kanadischen und US-amerikanischen Finanzm盲rkten zu st盲rken.
- None.
- None.
VANCOUVER, BC / / July 29, 2025 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company focused on developing therapeutics for rare and underserved diseases, today announced its formal engagement with ArcStone Securities and Investments Corp. ("ArcStone"), a capital markets advisory firm.
Under the terms of the agreement, ArcStone will provide Lobe Sciences with comprehensive advisory services, including capital markets planning, institutional investor engagement, and strategic positioning across North American markets. The collaboration is aimed at expanding Lobe's visibility within the investment community and reinforcing its long-term commitment to delivering shareholder value through scientific innovation and commercial execution.
"This engagement marks a meaningful step forward in our capital markets strategy," said Dr. Fred D. Sancilio, Chairman and CEO of Lobe Sciences. "ArcStone's deep expertise and extensive network in both Canadian and U.S. financial ecosystems will amplify our messaging, support our goals, and drive sustained value creation as we advance our development programs."
"We're honored to partner with Lobe Sciences at this important inflection point," added Steve Kann, Head of U.S. Banking at ArcStone. "Their unique pipeline addresses acute medical needs that have not been satisfied by the market. We look forward to helping the Company navigate public market dynamics and broaden institutional interest."
The agreement is effective immediately.
About Lobe Sciences Ltd.
Lobe Sciences Ltd. (CSE: LOBE | OTCQB: LOBEF | FWB: LOBE.F) is a growth-stage biopharmaceutical company developing advanced treatments for rare and neurologically underserved conditions. Through its wholly owned subsidiary, Altemia, Inc., and majority-owned Cynaptec Pharmaceuticals, Inc., Lobe is advancing a patented lipid-based delivery platform for the treatment of Sickle Cell Disease and a proprietary oral analog of psilocin-Conjugated Psilocin鈩�-targeted for Chronic Cluster Headache and related disorders. The Company's mission is to improve patient outcomes through innovation and precision-driven science.
About ArcStone Securities and Investments Corp.
ArcStone Securities and Investments. Corp. is a boutique investment advisory firm specializing in capital markets strategy, investor engagement, and financial communications for emerging growth companies. With a cross-border presence and tailored approach, ArcStone provides tactical guidance to issuers navigating public equity markets and optimizing capital structures.
Cautionary Statement Regarding "Forward-Looking" Information
This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation: the Company's intention to raise funds for clinical trials, the innovativeness of Conjugated PsilocinTM. the anticipated focus and timing or efficiency of the Company's research and development activities; the potential for the Company's products to meet unmet medical needs, the anticipated use of proceeds from the offering, the intended development plans for Cynaptec, the intention of Lobe Sciences to provide certain services to Cynaptec, the potential exercise of the option and intended use of proceeds therefrom and the potential ability to raise funds for clinical development are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should" or "would" or occur.
Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that: the Company's planned activities will be able to create shareholder value and address serious unmet medical needs; the Company will continue to pursue its planned research and development activities, and that the Company will be able to raise funds among others. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that: the Company's planned activities will be unable to create shareholder value or address the targeted unmet medical needs; the Company is unable to obtain the desired results from its current research and development activities; and the Company is unable to raise funds or to do so on the timelines anticipated.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS NEWS RELEASE.
For further information, please contact:
Dr. Fred D. Sancilio, CEO
Lobe Sciences Ltd.
Investor and Media
[email protected]
Phone: +1 (949) 505-5623
Email: [email protected]
Website:
SOURCE: Lobe Sciences Ltd.
View the original on ACCESS Newswire
FAQ
What services will ArcStone Securities provide to Lobe Sciences (LOBEF)?
Who is the CEO of Lobe Sciences (LOBEF)?
When does the partnership between Lobe Sciences and ArcStone Securities begin?
What is Lobe Sciences' (LOBEF) main business focus?
